Psychedelic Industry 2022 The Big Turnaround It was a wild 2021. We had NASDAQ uplists and multi-billion dollar IPOs. And despite some pretty extreme market fluctuations, the psychedelic medicine industry has managed to cement itself as a legitimate biotech sector worthy of investor confidence.
While 2022 hasn’t yet given us the market turnaround we had hoped for, the forthcoming 12 months will be filled with clinical trial news and significant milestones, and the current price pullback may present interesting opportunities for investors.